Y-mAbs Therapeutics (NASDAQ:YMAB) issued its quarterly earnings data on Wednesday. The company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.16), Fidelity Earnings reports.
YMAB traded down $0.51 on Thursday, hitting $28.17. 14,550 shares of the company were exchanged, compared to its average volume of 288,594. Y-mAbs Therapeutics has a twelve month low of $15.17 and a twelve month high of $32.90. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -18.83 and a beta of 1.19. The company has a current ratio of 9.04, a quick ratio of 9.04 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $27.74 and a two-hundred day moving average price of $24.79.
A number of equities research analysts have recently weighed in on the company. ValuEngine raised Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Monday, November 4th. Zacks Investment Research raised Y-mAbs Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 target price for the company in a research note on Saturday, November 9th. Wedbush started coverage on Y-mAbs Therapeutics in a research note on Tuesday, September 3rd. They set an “outperform” rating and a $38.00 target price for the company. Finally, Cowen reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Monday, October 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $38.75.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.